ORPHA:213823
Adenoid cystic carcinoma of the cervix uteri
Also known as: Cervical adenoid cystic carcinoma
Publications
82
32.6th percentile
Trials
0
Interventional, condition-specific
Researchers
336
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, highly aggressive uterine cancer, macroscopically appearing as an irregular, slow-growing, non-friable, polypoid mass on the uterine cervix and histologically showing a pseudoglandular or cribriform growth pattern. It presents with vaginal bleeding and discharge and abdominal or pelvic pain. The tumor is highly infiltrative, often associated with vascular, lymphatic and perineural invasion, with subsequent haematogenous spread and early recurrence.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006133
- UMLS:C1332911
- NCIT:C6346
Additional Mondo synonyms (10)
adenoid cystic carcinoma of cervix · adenoid cystic carcinoma of cervix uteri · adenoid cystic carcinoma of the cervix · adenoid cystic carcinoma of the cervix uteri · adenoid cystic carcinoma of the uterine cervix · adenoid cystic carcinoma of uterine cervix · cervical adenoid cystic cancer · cervical adenoid cystic carcinoma · cervix uteri adenoid cystic carcinoma · uterine cervix adenoid cystic carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
82 matched papers (15 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 92 for broader category adenoid cystic carcinoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
82
82 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
82 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
15 in the last 10 years · high confidence · 32.6th percentile (publications denominator)
Phrase hits: 82 · MeSH hits: 0
Who's working on it?
336
Distinct author names in 82 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Grayson W3 papers · 2003
Department of Anatomical Pathology, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, PO Box 1038, Johannesburg 2000, South Africa. wayneg@mail.saimr.wits.ac.za
Papers in Europe PMC - 02Baboo HA2 papers · 1994Papers in Europe PMC
- 03Dixit S2 papers · 1994
Dept. of Radiotherapy, Gujarat Cancer and Research Center, Asarwa, Ahmedabad.
Papers in Europe PMC - 04Gao HW2 papers · 2022
Department of Pathology, the Second Hospital of Jilin University, Changchun 130041, China.
Papers in Europe PMC - 05Grafton WD2 papers · 1976Papers in Europe PMC
- 06Guettier C2 papers · 1996Papers in Europe PMC
- 07He YY2 papers · 2022
Department of Pathology, the Second Hospital of Jilin University, Changchun 130041, China.
Papers in Europe PMC - 08Houissa-Vuong S2 papers · 1996Papers in Europe PMC
- 09Kashima K2 papers · 2005Papers in Europe PMC
- 10Miles PA2 papers · 1978Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 92 trials are registered for adenoid cystic carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
92 interventional trials matched adenoid cystic carcinoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: adenoid cystic carcinoma
92
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07755397·RECRUITING·First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
Conditions: NSCLC Patients With EGFR Activating Mutation · Adenoid Cystic Carcinoma Metastatic · Adenoid Cystic Carcinoma of the Head and Neck·Matched via name phrase
- NCT06462183·RECRUITING·Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Conditions: Adenoid Cystic Carcinoma · Colorectal Cancer·Matched via name phrase
- NCT07521670·NOT YET RECRUITING·Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
Conditions: Recurrent Adenoid Cystic Carcinoma · Adenoid Cystic Carcinoma Metastatic · Papillary Thyroid Carcinoma·Matched via name phrase
- NCT05774899·RECRUITING·CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Conditions: Adenoid Cystic Carcinoma · Metastatic Adenoid Cystic Carcinoma · Recurrent Adenoid Cystic Carcinoma·Matched via name phrase
- NCT05733910·RECRUITING·Simultaneous Integrated Boost in Carbon Ion Radiotherapy for Head and Neck Adenoid Cystic Carcinoma
Conditions: Carcinoma, Adenoid Cystic · Head and Neck Cancer·Matched via name phrase
- NCT07616141·NOT YET RECRUITING·Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma
Conditions: Adenoid Cystic Carcinoma·Matched via name phrase
- NCT06781567·RECRUITING·Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Conditions: Adenoid Cystic Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT01473784·RECRUITING·Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity · Recurrent Mucoepidermoid Carcinoma of the Oral Cavity · Recurrent Squamous Cell Carcinoma of the Hypopharynx · Recurrent Squamous Cell Carcinoma of the Larynx·Matched via name phrase
- NCT02838602·RECRUITING·Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors
Conditions: Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma·Matched via name phrase
- NCT07320508·RECRUITING·Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
Conditions: Adenoid Cystic Carcinoma · Sinonasal Carcinoma · Epirubicin·Matched via name phrase
- NCT07162480·RECRUITING·Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Conditions: Adenoid Cystic Carcinoma·Matched via name phrase
- NCT04214366·RECRUITING·Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
Conditions: Adenoid Cystic Carcinoma·Matched via name phrase
- NCT06805825·RECRUITING·A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Conditions: Gastrointestinal Stromal Tumors · Small-cell Lung Cancer · Adenoid Cystic Carcinoma · Uveal Melanoma·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT03556228·RECRUITING·VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Conditions: Head and Neck Carcinoma · Adenoid Cystic Carcinoma · Lung Cancer · Non-Small Cell Lung Cancer·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
- isrctn·ISRCTN14471479·Recruiting·How mouth bacteria affect radiation treatment for head and neck cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Adenoid cystic carcinoma of the cervix uteri — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Adenoid cystic carcinoma of the cervix uteri" OR "Adenoid cystic carcinoma of cervix uteri" OR "Cervical adenoid cystic carcinoma" OR "adenoid cystic carcinoma of cervix" OR "adenoid cystic carcinoma of the cervix" OR "adenoid cystic carcinoma of the uterine cervix" OR "adenoid cystic carcinoma of uterine cervix" OR "cervical adenoid cystic cancer" OR "cervix uteri adenoid cystic carcinoma" OR "uterine cervix adenoid cystic carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Adenoid cystic carcinoma of the cervix uteri" OR "Adenoid cystic carcinoma of cervix uteri" OR "Cervical adenoid cystic carcinoma" OR "adenoid cystic carcinoma of cervix" OR "adenoid cystic carcinoma of the cervix" OR "adenoid cystic carcinoma of the uterine cervix" OR "adenoid cystic carcinoma of uterine cervix" OR "cervical adenoid cystic cancer" OR "cervix uteri adenoid cystic carcinoma" OR "uterine cervix adenoid cystic carcinoma"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"adenoid cystic carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:40:02.903Z
